Pharmaceutical Technology

MARCH 24, 2023

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016.

Competition 59

Competition Marketing FDA Physicians 59

Clarify Health

MARCH 1, 2023

1] In a separate, controlled study, 80 percent of primary care physicians receiving micro-incentives referred patients to higher-value specialists they had never used before — representing a significant reduction in the total cost of care. Healthcare (2016), [link] [2] Parikh, R. million on orthopedic MS-DRGs.[1]

Physicians 52

Physicians Prescription Medicine Healthcare 52

pharmaphorum

DECEMBER 2, 2022

Enrolling for clinical trials has become more challenging in recent years, with trial competition, increasingly complex protocols, and precision medicine targeting more niche patient populations. Integrating real-world data and healthcare treatment trends at the site level can mitigate challenges throughout the lifetime of the study.

Competition 96

Competition Leads Patients Electronics 96

Evolve Your Success

MAY 23, 2023

With VR simulations, sales reps can now hone their skills in lifelike scenarios, giving them a competitive edge in the field. But VR’s potential doesn’t stop there; it’s poised to revolutionize everything from healthcare to education. Osso was founded in 2016. My initial focus was I wanted to be a physician.

Training 52

Training Medical Sales Medical sales 52

pharmaphorum

JUNE 29, 2022

Health systems have had to spend to address backlogs, make healthcare delivery COVID-resilient and deal with long COVID, as well as addressing COVID itself – and, as previously noted, COVID vaccines constitute a significant incremental global spend. Launches, therefore, were happening. But were they fulfilling their commercial potential?

Doctors 57

Doctors Medicine Marketing Prescription 57

Clarivate

MAY 24, 2023

In recent years, FDA has increasingly shown an openness to surrogate endpoints as the basis for approval of a therapy,” said Bethany Kiernan, Director of Healthcare Research Analytics for Infectious, Niche and Rare Diseases at Clarivate.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Pharmaceutical Technology

DECEMBER 4, 2022

Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Indeed, Amgen’s biosimilar was approved in September 2016, but the company was not able to launch it until January 2023 in the US. Biosimilar uptake could be more gradual.

Marketing 104

Marketing Physicians Competition Patients 104